Add to Calendar 3/21/2019 8:00:00 AM 3/21/2019 10:00:00 AM Overcoming Challenges in Immuno Oncology Clinical Trials Aimed at those who are eager to hear about and discuss some of the latest developments in Cancer Immno oncology (IO), our distinguished panel will focus the forum discussion on dose-finding, biomarker development and endpoints for IO and IO-IO combination clinical trials. For those not familiar with IO we’ll provide a brief including basic principles and a few examples like checkpoint inhibitors. We’ll explore what is different for IO and for IO-IO combinations dose finding compared with traditional chemo dose finding. You’ll learn about new strategies underway for IO biomarker development that can help speed up development such as seamless adaptive designs, introduction of Bayesian paradigm into frequentist designs, and more. Finally, we will wrap up with a look at modern techniques for clinical trial endpoints and statistics including PFS versus OS as primary and RECIST vs irRECIST. Come join this interactive conversation. MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139
Senior Director, External Innovation, Ipsen
David Jenkins is currently a Senior Director in the External Innovation group at Ipsen, helping the company to grow its Oncology pipeline. Prior to Ipsen, David led the Immuno-Oncology Translational Research and Development group at TESARO, developing a large network of academic and industrial collaborators to advance therapeutic antibodies directed to PD-1, Tim-3 and LAG-3 into the clinic and provide support to earlier programs. He has also held various program leadership and R&D positions at AstraZeneca/MedImmune and Novartis with a focus on biologic/small molecule therapies and Immuno-Oncology. David received his Master’s and PhD from the University of Cambridge, U.K.